



## Vicore announces participation in investor meetings during June 2021

Gothenburg, June 15, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the participation in two upcoming investor meetings in June 2021.

**Date: Wednesday, 23 June, 2021**

**Presentation: 16:40 CET (10:40 AM EDT)**

**Event and registration: [NewYorkBIO/NYSE Emerging Biotech Company Showcase](#)**

CEO Carl-Johan Dalsgaard will present an overview of the company's business strategy at the joint NewYorkBIO and New York Stock Exchange (NYSE) Emerging Biotech Company Showcase to be held virtually on 23 June 2021. The presentation is followed by a Q&A session.

**Date: Tuesday, 29 June 2021**

**Presentation: 14.30 CET (8:30 AM EDT)**

**Event and registration: [Nordic Biotech Summit](#)**

CEO Carl-Johan Dalsgaard will also present the company's business strategy at the Nordic Biotech Summit organized by LifeSci Advisors on 29 June 2021. The meeting will take place virtually. The presentation is followed by a Q&A session and Carl-Johan and CFO Hans Jeppsson will be available for one-to-one investor meetings throughout the day.

**For further information:**

Carl-Johan Dalsgaard, CEO

Tel: +46 70 975 98 63

E: [carl-johan.dalsgaard@vicorepharma.com](mailto:carl-johan.dalsgaard@vicorepharma.com)

*This information was submitted for publication on June 15, 2021 at 08:00 CET.*

**About Vicore Pharma Holding AB (publ)**

*Vicore Pharma is a rare disease pharmaceutical company focused on fibrotic lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.*

*The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see [www.vicorepharma.com](http://www.vicorepharma.com).*